Neuromyelitis Optica

This is a rare autoimmune disease that affects the brain and spinal cord. It causes inflammation and damage to the optic nerves (the nerves that connect the eye to the brain) and the spinal cord. This damage can lead to vision loss, weakness, numbness, and problems with bladder control. It's sometimes called Devic's Disease.

Condition

What people with Neuromyelitis Optica report

Every report comes from a Lived member, sent anonymously.

Have you tried Solu-Medrol (Methylprednisolone Hemisuccinate) for Neuromyelitis Optica?

NameHow it went

About Neuromyelitis Optica

What It Is

Neuromyelitis optica, now usually called neuromyelitis optica spectrum disorder (NMOSD), is a rare autoimmune condition in which the immune system attacks the optic nerves, which carry vision from the eyes to the brain, and the spinal cord. It typically comes as attacks. An attack on an optic nerve (optic neuritis) causes eye pain and loss of vision, sometimes in both eyes at once. An attack on the spinal cord (myelitis) can cause weakness or paralysis of the legs or arms, numbness, and loss of bladder or bowel control. Some attacks affect the brainstem instead, causing persistent nausea, vomiting or hiccups that ordinary remedies do not settle. What makes NMOSD serious is that attacks can be severe and recovery is often incomplete, so damage can build up with each one. Most people have a relapsing form, with attacks separated by months or years; a less common form happens only once. NMOSD was long thought to be a type of multiple sclerosis (MS), but it is a distinct disease with different treatment.

Causes & Risk Factors

In most people with NMOSD, the immune system makes antibodies against aquaporin-4, a protein on support cells that help protect nerves in the optic nerves and spinal cord. These antibodies set off inflammation that injures those cells and, in turn, the nerves. Why the immune system starts doing this is not known. NMOSD usually does not run in families; more than 95% of people with it have no affected relatives. It is more common in women, who are four to five times more likely than men to have the relapsing antibody-positive form, and, compared with MS, it affects people of African and Asian descent more often. A personal or family history of other autoimmune conditions, such as lupus, is common, and NMOSD sometimes occurs alongside lupus. NMOSD can start at any age, including childhood, but often begins around the 40s.

How It's Diagnosed

Diagnosis combines the pattern of symptoms with a blood test and imaging. The key blood test looks for aquaporin-4 antibodies (AQP4 antibodies). A positive result is highly specific, meaning it rarely appears in people without NMOSD, and it is often positive from the very first attack. A negative result does not fully rule NMOSD out, though: some people never test positive, and their diagnosis depends on stricter clinical and MRI findings. Some of them instead have antibodies to a different protein, myelin oligodendrocyte glycoprotein (MOG), which points to a related but separate condition with its own outlook. MRI (magnetic resonance imaging) of the spine often shows inflammation stretching along a long section of the cord, and imaging of the optic nerves may show long or far-back lesions. The brain MRI is often normal early on, and a spinal tap usually does not show the antibody markers (oligoclonal bands) typical of MS. These differences matter because NMOSD and MS can look alike at first, yet medicines used for MS do not prevent NMOSD attacks, and one of them, interferon beta, may make it worse. Doctors also consider look-alikes such as sarcoidosis and other causes of spinal cord inflammation.

Treatment Options

Treatment has two parts: stopping an attack quickly and preventing the next one. An attack is treated as a medical emergency, usually with high-dose intravenous corticosteroids (such as methylprednisolone). Plasma exchange, a procedure that filters antibodies out of the blood, is often added, especially when steroids alone are not working. Treatment starts as soon as an attack is suspected, without waiting for antibody results, because faster treatment gives the best chance of recovering vision or movement. Long-term prevention is the core of care, since each attack can leave lasting damage. Four medicines are approved by the US Food and Drug Administration (FDA) for adults who test positive for aquaporin-4 antibodies. Eculizumab (Soliris) and ravulizumab (Ultomiris) block part of the immune system called complement and are given by IV infusion, every two weeks and every eight weeks respectively after starting doses. Inebilizumab (Uplizna) removes the immune cells that produce antibodies and is given as an IV infusion every six months after two starting doses. Satralizumab (Enspryng) blocks the immune signal interleukin-6 and is a self-injected shot under the skin every four weeks. In randomized trials, these antibody medicines cut the risk of relapse to roughly a fifth of that in comparison groups. Older, broader immunosuppressants, including rituximab, mycophenolate mofetil and azathioprine, are used off label, sometimes with low-dose steroids, and remain common choices, particularly for people who are antibody negative. The main trade-off with all of these is a higher risk of infection, with screening and blood tests along the way. For eculizumab and ravulizumab, that includes a serious risk of meningococcal infection (a bacterial cause of meningitis and bloodstream infection), so meningococcal vaccines are required before starting. Choosing among options depends on antibody status, how active the disease has been, pregnancy plans, side effects and how often a person can travel for infusions. Care also covers the effects of past attacks: medicines and therapies for nerve pain, muscle stiffness and spasms, and bladder or bowel problems, along with physical and occupational therapy, vision support and mobility aids.

What to Expect

NMOSD is a long-term condition, but its course depends heavily on preventing attacks. Many people recover partly after an attack, especially with prompt treatment, yet some lasting loss of vision, strength, sensation or bladder control is common, and repeated attacks can lead to blindness or difficulty walking. With effective preventive treatment, many people go long stretches without a relapse and keep working and living independently. Daily life often involves managing leftover symptoms such as nerve pain, fatigue, stiffness and bladder urgency, alongside a regular schedule of infusions or injections, blood tests and visits with a neurologist, ideally one experienced in NMOSD. Eye, urology and rehabilitation specialists may join the team depending on which parts of the nervous system have been affected. Patient organizations and support groups can help with the practical and emotional load of a rare disease. Pregnancy is considered high risk with NMOSD. The chance of an attack rises in the months after delivery, and some preventive medicines need to be changed or timed around pregnancy, so it helps to plan with both the neurologist and an obstetrician before conceiving.

When to Seek Help

See a doctor promptly, and ask about NMOSD testing, if you have had unexplained vision loss with eye pain, a spinal cord inflammation episode, or vomiting and hiccups that would not stop, particularly if MS has been suggested but the picture does not quite fit. If you already have NMOSD, new or worsening vision loss, eye pain, weakness, numbness, loss of bladder or bowel control, or vomiting and hiccups that will not settle may signal an attack. Contact your neurology team the same day, or go to an emergency department if you cannot reach them, because attack treatment works best when it starts quickly. If you take eculizumab or ravulizumab, get emergency care right away for fever, fever with a rash, headache with a stiff neck, or confusion, since meningococcal infection can become life-threatening within hours.

Questions to Ask Your Doctor

  1. 1.Have I been tested for aquaporin-4 and MOG antibodies, and how do the results change my diagnosis and treatment?
  2. 2.Which preventive treatment do you recommend for me, and how does it compare with the others in effectiveness, schedule and infection risk?
  3. 3.What exactly should I do, and whom should I call, if I think I am having an attack?
  4. 4.How will we track whether the treatment is working, and what tests or vaccines will I need along the way?
  5. 5.If I want to become pregnant, how should my treatment and monitoring change before, during and after pregnancy?

Last reviewed • Oct 2026

Educational content, not medical advice.